会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 43. 发明公开
    • Prodrug comprising a drug linker conjugate
    • Prodrug beinhaltend ein Wirkstoff-Linker Konjugat
    • EP2596805A1
    • 2013-05-29
    • EP13156350.4
    • 2009-01-30
    • Ascendis Pharma A/S
    • Cleemann, FelixHersel, UlrichKaden-Vagt, SilviaRau, HaraldWegge, Thomas
    • A61K47/48
    • A61K47/48215A61K31/553A61K38/1709A61K38/18A61K38/26A61K47/54A61K47/542A61K47/545A61K47/60A61K47/65
    • The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising a drug linker conjugate D-L, wherein
      -D is an amine containing biologically active moiety; and
      -L is a
      non-biologically active linker moiety -L 1 represented by formula (I),

      wherein the dashed line indicates the attachment to the amine of the biologically active moiety and wherein R 1 , R 1a , R 2 , R 2a , R 3 , R 3a , X, X 1 , X 2 , X 3 have the meaning as indicated in the description and the claims and wherein L 1 is substituted with one to four groups L 2 -Z and optionally further substituted, provided that the hydrogen marked with the asterisk in formula (I) is not replaced by a substituent; wherein L 2 is a single chemical bond or a spacer; and Z is a carrier group and wherein D-H is a polypeptide selected from the group of polypeptides consisting of exendins, glucagon, glucagon-like peptides and insulins. The invention also relates pharmaceutical composition comprising said prodrugs and their use as medicaments.
    • 本发明涉及包含药物连接物缀合物D-L的前药或其药学上可接受的盐,其中-D是含胺的生物活性部分; 和-L是由式(I)表示的非生物活性的连接体部分-L 1,其中虚线表示与生物活性部分的胺的连接,并且其中R 1,R 1a,R 2,R 2a, R 3,R 3a,X,X 1,X 2,X 3具有如说明书和权利要求书中所示的含义,并且其中L 1被一至四个L 2 -Z基团任选地进一步取代,条件是 用式(I)中的星号标记的氢不被取代基取代; 其中L 2是单个化学键或间隔基; 并且Z是载体基团,并且其中D-H是选自由毒蜥外泌肽,胰高血糖素,胰高血糖素样肽和胰岛素组成的多肽组的多肽。 本发明还涉及包含所述前药的药物组合物及其作为药物的用途。